The ocular endothelin system: a novel target for the treatment of wndotoxin-induced uveitis with bosentan
View/ Open
Access
info:eu-repo/semantics/openAccessDate
2014Author
Keleş, SadullahHalıcı, Zekai
Atmaca, Hasan Tarık
Yayla, Muhammed
Yıldırım, Kenan
Ekinci, Metin
Akpınar, Erol
Altuner, Durdu
Çakıcı, Özgür
Bayraktutan, Zafer
Metadata
Show full item recordCitation
Keles, S., Halici, Z., Ataca, H.T., Yayla, M., Yildirim, K., Ekinci, M., Akpinar, E. ve diğerleri (2014). The ocular endothelin system: a novel target for the treatment of wndotoxin-induced uveitis with bosentan. Investigative Ophthalmology & Visual Science, 55(6), 3517-3524. https://doi.org/10.1167/iovs.14-14193Abstract
PURPOSE. We compared the anti-inflammatory effects of bosentan and dexamethasone in endotoxin-induced uveitis (EIU). METHODS. Endotoxin-induced uveitis was induced by subcutaneous injection of lipopolysaccharide (LPS, 200 mu g) in Wistar rats. Rats were divided randomly into 10 groups (n=6). Bosentan at doses of 50 and 100 mg/kg were administered orally 1 hour before and 12 hours after LPS injection, and dexamethasone was administered by intraperitoneally 30 minutes before and 30 minutes after LPS injection at a dose of 1 mg/kg. Data were collected at two time points for each control and treatment; animals were killed at either 3 or 24 hours after LPS injection. Histopathologic evaluation and aqueous humour measurements of TNF-alpha level were performed, and endothelin-1 (ET-1), inducible nitric oxide synthase (iNOS), and endothelin receptor A and B (EDNRA and B) expression were analyzed. RESULTS. the group treated with 100 mg/kg bosentan at 24 hours displayed significantly milder uveitis and fewer inflammatory cells compared to LPS-injected animals, and there were similar findings in the dexamethasone-treated group at 24 hours. the TNF-alpha levels in the dexamethasone treatment group were lower than those in the LPS-induced uveitis control group (P < 0.05); however, there was no difference between the dexamethasone and bosentan treatment groups at 3 and 24 hours after LPS administration. Bosentan treatment at doses of 50 and 100 mg/kg significantly decreased iNOS expression compared to LPS-injected animals (P < 0.001). the ET-1 expression was suppressed significantly by bosentan and dexamethasone at 3 and 24 hours after LPS administration (P < 0.001). the EDNRA expression in the bosentan treatment groups was statistically significantly lower than that in the LPS-induced uveitis control group at 3 and 24 hours after LPS administration (P < 0.05). CONCLUSIONS. Bosentan reduces intraocular inflammation and has similar effects as dexamethasone in a rat model of EIU.